HF
NBRV

HRT Financial’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

HRT Financial’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-453
Closed -$4K – 4125
2022
Q1 		$4K Buy
+453
New +$5.5K ﹤0.01% 2976
2020
Q2 		– Sell
-72
Closed -$10K – 1844
2020
Q1 		$10K Buy
+72
New +$22K ﹤0.01% 692
2019
Q1 		– Sell
-86
Closed -$31K – 880
2018
Q4 		$31K Buy
+86
New +$46.2K ﹤0.01% 545

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

HRT Financial's NBRV Position: Q2 2022 in Review

HRT Financial sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2022, closing a stake of 453 shares — an estimated $4K sold.

HRT Financial first reported a position in NBRV in Q4 2018 and held it in 3 quarters. The position peaked at $31K in Q4 2018. 25 funds tracked by Wall St. Rank hold NBRV as of Q2 2022.

  • HRT Financial reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2022 after selling out during the quarter.
  • HRT Financial sold 453 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2022, an estimated $4K.
  • HRT Financial first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2018 and held it in 3 quarters.
  • HRT Financial's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $31K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2022.

Based on HRT Financial's 13F filing for Q2 2022, filed 12 Aug 2022.